Your browser doesn't support javascript.
loading
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Morales-Barrera, Rafael; Villacampa, Guillermo; Vidal, Natalia; Figols, Mariona; Giner, Julia; Bonfill, Teresa; Suárez, Cristina; Díaz, Nely; Mateo, Joaquín; González, Macarena; Domenech, Montserrat; Puente, Javier; Carles, Joan.
Afiliação
  • Morales-Barrera R; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain. rmorales@vhio.net.
  • Villacampa G; Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vidal N; The Institute of Cancer Research, London, UK.
  • Figols M; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Giner J; Medical Oncology Department, Fundació Althaia Manresa, Manresa, Spain.
  • Bonfill T; Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain.
  • Suárez C; Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain.
  • Díaz N; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain.
  • Mateo J; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain.
  • González M; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain.
  • Domenech M; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Catalonia, Spain.
  • Puente J; Medical Oncology Department, Fundació Althaia Manresa, Manresa, Spain.
  • Carles J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
Clin Transl Oncol ; 25(12): 3556-3564, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37217634
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha